HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Serum levels of BAFF, but not APRIL, are increased after rituximab treatment in patients with primary Sjogren's syndrome: data from a placebo-controlled clinical trial.

AuthorsRodney P E Pollard, Wayel H Abdulahad, Arjan Vissink, Nishath Hamza, Johannes G M Burgerhof, Jiska M Meijer, Annie Visser, Minke G Huitema, Fred K L Spijkervet, Cees G M Kallenberg, Hendrika Bootsma, Frans G M Kroese
JournalAnnals of the rheumatic diseases (Ann Rheum Dis) Vol. 72 Issue 1 Pg. 146-8 (Jan 2013) ISSN: 1468-2060 [Electronic] England
PMID22851468 (Publication Type: Letter, Randomized Controlled Trial)
Chemical References
  • Antibodies, Monoclonal, Murine-Derived
  • Antirheumatic Agents
  • B-Cell Activating Factor
  • TNFSF13B protein, human
  • Tumor Necrosis Factor Ligand Superfamily Member 13
  • Rituximab
Topics
  • Antibodies, Monoclonal, Murine-Derived (therapeutic use)
  • Antirheumatic Agents (therapeutic use)
  • B-Cell Activating Factor (blood)
  • Double-Blind Method
  • Enzyme-Linked Immunosorbent Assay
  • Humans
  • Rituximab
  • Sjogren's Syndrome (blood, drug therapy)
  • Tumor Necrosis Factor Ligand Superfamily Member 13 (blood)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: